Prelude Therapeutics Inc — Director's Dealing 2021

Apr 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2021-04-07

Reporting Person: Scherle Peggy (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-07	Common Stock	A	15370	$1.43	Acquired	188290	Direct
2021-04-07	Common Stock	S	8289	$39.0162	Disposed	180001	Direct
2021-04-07	Common Stock	S	6881	$39.6278	Disposed	173120	Direct
2021-04-07	Common Stock	S	200	$40.30	Disposed	172920	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-07	Employee Stock Option (right to buy)	$1.43	M	15370	Disposed	2028-11-12	Common Stock (15370)	Direct

Footnotes

F1: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.

F2: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F5: The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.